[
  {
    "ts": "2026-02-12T01:39:14+00:00",
    "headline": "Inspire Medical Systems Q4 Earnings Call Highlights",
    "summary": "Inspire Medical Systems (NYSE:INSP) management focused much of its fourth-quarter and full-year 2025 earnings call on reimbursement and coding uncertainty tied to the company’s Inspire 5 system, while also highlighting continued revenue growth, improved margins, and operational progress in the U.S.",
    "url": "https://www.marketbeat.com/instant-alerts/inspire-medical-systems-q4-earnings-call-highlights-2026-02-11/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "eb5d3de6-a8f5-3679-be20-b580fde4951d",
      "content": {
        "id": "eb5d3de6-a8f5-3679-be20-b580fde4951d",
        "contentType": "STORY",
        "title": "Inspire Medical Systems Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Inspire Medical Systems (NYSE:INSP) management focused much of its fourth-quarter and full-year 2025 earnings call on reimbursement and coding uncertainty tied to the company’s Inspire 5 system, while also highlighting continued revenue growth, improved margins, and operational progress in the U.S.",
        "pubDate": "2026-02-12T01:39:14Z",
        "displayTime": "2026-02-12T01:39:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/defc2d8f2f1ceb93a4cce58f7e44cd6f",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Inspire Medical Systems logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T5tddF11cMJsNJhuFfY5RA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/defc2d8f2f1ceb93a4cce58f7e44cd6f.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I6Ud3Ww8_dye_cUVWbvJYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/defc2d8f2f1ceb93a4cce58f7e44cd6f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/inspire-medical-systems-q4-earnings-call-highlights-2026-02-11/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/inspire-medical-systems-q4-earnings-013914813.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INSP"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T01:25:00+00:00",
    "headline": "I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now?",
    "summary": "Energy stocks are in the spotlight, and ExxonMobil is best in breed.",
    "url": "https://www.fool.com/investing/2026/02/11/exxonmobil-trillion-club-2030-buy-dividend-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "af1600bd-5924-3e2b-9cfa-d6a9a5d559ed",
      "content": {
        "id": "af1600bd-5924-3e2b-9cfa-d6a9a5d559ed",
        "contentType": "STORY",
        "title": "I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now?",
        "description": "",
        "summary": "Energy stocks are in the spotlight, and ExxonMobil is best in breed.",
        "pubDate": "2026-02-12T01:25:00Z",
        "displayTime": "2026-02-12T01:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/7f6d374928b676aa589976888024a5bb",
          "originalWidth": 1201,
          "originalHeight": 800,
          "caption": "An offshore oil rig flaring excess natural gas.  ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VUm83WOpNoIJaXLyvaRpsA--~B/aD04MDA7dz0xMjAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/7f6d374928b676aa589976888024a5bb.cf.webp",
              "width": 1201,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QMkxLWuKRE_OEi8Lj3nVnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/7f6d374928b676aa589976888024a5bb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/exxonmobil-trillion-club-2030-buy-dividend-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/predicted-exxonmobil-join-1-trillion-012500780.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XOM"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "BRK.A"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "V"
            },
            {
              "symbol": "ORCL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T00:38:43+00:00",
    "headline": "Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion in cash. The acquisition gives Lilly access to a technology platform designed to allow […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-acquire-003843982.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "036c468e-588c-3faa-9a74-5ac4811a6ee0",
      "content": {
        "id": "036c468e-588c-3faa-9a74-5ac4811a6ee0",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion in cash. The acquisition gives Lilly access to a technology platform designed to allow […]",
        "pubDate": "2026-02-12T00:38:43Z",
        "displayTime": "2026-02-12T00:38:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-acquire-003843982.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-acquire-003843982.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T10:30:00+00:00",
    "headline": "Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.",
    "summary": "Both companies are betting on interest in weight loss pills.",
    "url": "https://www.fool.com/investing/2026/02/12/eli-lilly-vs-novo-nordisk-in-weight-loss-market/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "19b8a5e1-551e-3af2-b5a3-90495b78df3e",
      "content": {
        "id": "19b8a5e1-551e-3af2-b5a3-90495b78df3e",
        "contentType": "STORY",
        "title": "Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.",
        "description": "",
        "summary": "Both companies are betting on interest in weight loss pills.",
        "pubDate": "2026-02-12T10:30:00Z",
        "displayTime": "2026-02-12T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/912c34855aa88b075b13bd89687dc931",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor takes notes while working at a computer.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_2EpCgbStLgbVyGEtzRGCg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/912c34855aa88b075b13bd89687dc931.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Mrk3VtgTf79Qr54REnhTjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/912c34855aa88b075b13bd89687dc931.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/12/eli-lilly-vs-novo-nordisk-in-weight-loss-market/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-vs-novo-nordisk-103000865.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T10:13:43+00:00",
    "headline": "Eli Lilly Expands Beyond Obesity With Orna Deal And New Partnerships",
    "summary": "Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics to build out its in vivo cell and gene therapy capabilities for autoimmune diseases. The deal is paired with new partnerships in immunology and oncology, including collaborations with Innovent Biologics and Repertoire Immune Medicines. These moves reflect a push to expand beyond obesity and diabetes medicines into next generation treatment platforms. Eli Lilly, known for its diabetes and obesity drugs, is now putting more weight...",
    "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-obesity-101343681.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "275b7058-b8b1-3aea-a8b8-80999eef4f79",
      "content": {
        "id": "275b7058-b8b1-3aea-a8b8-80999eef4f79",
        "contentType": "STORY",
        "title": "Eli Lilly Expands Beyond Obesity With Orna Deal And New Partnerships",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics to build out its in vivo cell and gene therapy capabilities for autoimmune diseases. The deal is paired with new partnerships in immunology and oncology, including collaborations with Innovent Biologics and Repertoire Immune Medicines. These moves reflect a push to expand beyond obesity and diabetes medicines into next generation treatment platforms. Eli Lilly, known for its diabetes and obesity drugs, is now putting more weight...",
        "pubDate": "2026-02-12T10:13:43Z",
        "displayTime": "2026-02-12T10:13:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-obesity-101343681.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-beyond-obesity-101343681.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T13:02:37+00:00",
    "headline": "'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market",
    "summary": "McDonald's CEO prepares to battle weight-loss drug pills.",
    "url": "https://finance.yahoo.com/news/we-know-that-consumers-behavior-changes-mcdonalds-prepares-for-wider-glp-1-adoption-as-weight-loss-pills-hit-market-130237799.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "9026c272-93cb-4355-9b6e-128b98e18722",
      "content": {
        "id": "9026c272-93cb-4355-9b6e-128b98e18722",
        "contentType": "STORY",
        "title": "'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market",
        "description": "",
        "summary": "McDonald's CEO prepares to battle weight-loss drug pills.",
        "pubDate": "2026-02-12T13:02:37Z",
        "displayTime": "2026-02-12T13:02:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/3dca3830-07f9-11f1-b9eb-07ad18b99276",
          "originalWidth": 3488,
          "originalHeight": 2325,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IKkB19Lttv2diifHHustAg--~B/aD0yMzI1O3c9MzQ4ODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/3dca3830-07f9-11f1-b9eb-07ad18b99276.cf.webp",
              "width": 3488,
              "height": 2325,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3Lhu0WAM6IkZw4aD4qyCtg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/3dca3830-07f9-11f1-b9eb-07ad18b99276.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/we-know-that-consumers-behavior-changes-mcdonalds-prepares-for-wider-glp-1-adoption-as-weight-loss-pills-hit-market-130237799.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/we-know-that-consumers-behavior-changes-mcdonalds-prepares-for-wider-glp-1-adoption-as-weight-loss-pills-hit-market-130237799.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MCD"
            },
            {
              "symbol": "PEP"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T12:02:01+00:00",
    "headline": "West Pharma forecasts 2026 profit above estimates on strong demand for drug components",
    "summary": "Feb 12 () - West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on ‌strong demand for its proprietary products, which include syringes ‌and cartridges for injectable drugs. Shares of the Pennsylvania-based firm were up 3.",
    "url": "https://finance.yahoo.com/news/west-pharma-forecasts-2026-profit-120201797.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e8e27aa9-6594-38e5-9199-2c8a7fdb79ba",
      "content": {
        "id": "e8e27aa9-6594-38e5-9199-2c8a7fdb79ba",
        "contentType": "STORY",
        "title": "West Pharma forecasts 2026 profit above estimates on strong demand for drug components",
        "description": "",
        "summary": "Feb 12 () - West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on ‌strong demand for its proprietary products, which include syringes ‌and cartridges for injectable drugs. Shares of the Pennsylvania-based firm were up 3.",
        "pubDate": "2026-02-12T12:02:01Z",
        "displayTime": "2026-02-12T12:02:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/west-pharma-forecasts-2026-profit-120201797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/west-pharma-forecasts-2026-profit-120201797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WST"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]